MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report 1-800-533-1710

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,PLSD	SA00052377	3	F	SA00052377
Ordering Phys CLIENT,CLIENT				**DOB** 11/10/2009
Client Order # SA00052377	**Account Information**			**Report Notes**
Collected 12/27/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 02/15/2013 13:05				

Test	Flag	Results	Unit	Reference Value	Perform Site*
LysoPC by LC MS/MS (Reflex), BS			REPORTED 12/28/2012 10:57		
C20 Lysophosphatidylcholine		0.14	mcg/mL	<=0.20	MCR
C22 Lysophosphatidylcholine		<0.04	mcg/mL	<=0.10	MCR
C24 Lysophosphatidylcholine		0.11	mcg/mL	<=0.20	MCR
C26 Lysophosphatidylcholine		0.17	mcg/mL	<=0.20	MCR
Reviewed By		Jennifer Peterson			MCR
Interpretation (LPCBS)					MCR

In this sample, the concentrations of C20 to C26 lysophosphatidylcholine species are normal. Please note that this assay does not rule out all known peroxisomal disorders and is not designed to determine carrier status. Please contact the Biochemical Genetics consultant or genetic counselor on call (1-800-533-1710) if you have any questions or to determine if additional testing is warranted.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Laboratory developed test using analyte specific reagents. This test was developed, validated and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Lysosomal/Peroxisomal D/O Scrn, BS			REPORTED 12/28/2012 10:49		
Acid Beta-Glucosidase		9.7	nmol/mL/h	>=3.0	MCR
Sphingomyelinase		10.6	nmol/mL/h	>=5.5	MCR
Acid Alpha-Glucosidase		5.5	nmol/mL/h	>=4.0	MCR
Galactocerebrosidase		3.4	nmol/mL/h	>=0.4	MCR
Alpha-Galactosidase		7.2	nmol/mL/h	>=4.0	MCR
Alpha-L-Iduronidase		4.1	nmol/mL/h	>=2.0	MCR
C20 Lysophosphatidylcholine		0.12	mcg/mL	<=0.26	MCR
C22 Lysophosphatidylcholine		0.02	mcg/mL	<=0.11	MCR
C24 Lysophosphatidylcholine		0.06	mcg/mL	<0.10	MCR
C26 Lysophosphatidylcholine	H	0.34	mcg/mL	<=0.30	MCR
Interpretation (PLSD)					MCR

In this sample, the activities of the following enzymes (acid beta-glucosidase, acid alpha-glucosidase, sphingomyelinase, galactocerebrosidase, alpha-galactosidase, and alpha-L-iduronidase) are normal indicating that this patient is not affected with the lysosomal storage disorders caused by deficiencies in these enzymes. Please note that this assay does not rule out all known lysosomal storage disorders and is not designed to determine carrier status. Enzyme levels may be normal in patients receiving enzyme replacement therapy or who have

Performing Site Legend on Last Page of Report

* Report times for Mayo performed tests are CST/CDT

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,PLSD	SA00052377	3	F	SA00052377
Ordering Phys CLIENT,CLIENT				**DOB** 11/10/2009
Client Order # SA00052377	**Account Information**			**Report Notes**
Collected 12/27/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE ROCHESTER,MN 55901			
Printed 02/15/2013 13:05				

Test	Flag	Results	Unit	Reference Value	Perform Site*
undergone bone marrow transplantation. Because of the presence of compounds interfering with an accurate identification of C26 lysoPC, the sample has been re-analyzed by LC MS/MS. An interpretive comment and the concentrations for each lysoPC fraction will be provided in the LysoPC by LC MS/MS (Reflex), BS report. Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS) Laboratory developed test using analyte specific reagents. This test was developed, validated and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.					
Reviewed By		Jennifer Peterson			MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: